Avalo Therapeutics (AVTX)

• Market cap: $689M
• 1 day: 1.55%
• 5 days: -4.45%
• 1 month: -35.31%
• 3 months: -22.62%
• 6 months: -34.34%
• Year to date: -23.03%
• 1 year: 171.78%
• 5 years: -99.87%
• 10 years: -99.81%
• Sector: Healthcare
• Industry: Biotechnology

About: Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.

Employees: 33